AU5893696A - Modification of polypeptides - Google Patents

Modification of polypeptides

Info

Publication number
AU5893696A
AU5893696A AU58936/96A AU5893696A AU5893696A AU 5893696 A AU5893696 A AU 5893696A AU 58936/96 A AU58936/96 A AU 58936/96A AU 5893696 A AU5893696 A AU 5893696A AU 5893696 A AU5893696 A AU 5893696A
Authority
AU
Australia
Prior art keywords
polypeptides
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU58936/96A
Inventor
Thomas Christian Beck
Arne Agerlin Olsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU5893696A publication Critical patent/AU5893696A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/24—Organic nitrogen compounds
    • A21D2/26—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/0005—Other compounding ingredients characterised by their effect
    • C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/37—Polymers
    • C11D3/3703—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C11D3/3719—Polyamides or polyimides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole
    • A61K2800/72—Hypo-allergenic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU58936/96A 1995-06-07 1996-06-07 Modification of polypeptides Abandoned AU5893696A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK639/95 1995-06-07
DK63995 1995-06-07
PCT/DK1996/000249 WO1996040791A1 (en) 1995-06-07 1996-06-07 Modification of polypeptides

Publications (1)

Publication Number Publication Date
AU5893696A true AU5893696A (en) 1996-12-30

Family

ID=8095867

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58936/96A Abandoned AU5893696A (en) 1995-06-07 1996-06-07 Modification of polypeptides

Country Status (2)

Country Link
AU (1) AU5893696A (en)
WO (1) WO1996040791A1 (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030933A (en) * 1995-12-29 2000-02-29 The Procter & Gamble Company Detergent compositions comprising immobilized enzymes
WO1997030148A1 (en) * 1996-02-15 1997-08-21 Novo Nordisk A/S Conjugation of polypeptides
US6106828A (en) * 1996-02-15 2000-08-22 Novo Nordisk A/S Conjugation of polypeptides
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
CN1301305A (en) 1998-03-26 2001-06-27 宝洁公司 Serine protease variants having amino acid substitutions
US6936249B1 (en) 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6642011B2 (en) 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
MXPA02000842A (en) 1999-07-22 2002-07-30 Procter & Gamble Protease conjugates having sterically protected clip sites.
CZ2002220A3 (en) 1999-07-22 2002-05-15 The Procter & Gamble Company Subtilisin protease variants with deletions and substitution of amino acids in defined epitope regions
CZ2002212A3 (en) 1999-07-22 2002-07-17 The Procter & Gamble Company Variants of subtilisin protease having amino acid substitutions in defined epitope regions
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
ES2327606T3 (en) 2000-01-10 2009-11-02 Maxygen Holdings Ltd CONJUGATES OF G-CSF.
DE60138364D1 (en) 2000-02-11 2009-05-28 Bayer Healthcare Llc CLEANING FACTOR VII OR VIIA CONJUGATE
YU48703A (en) 2001-02-27 2006-05-25 Maxygen Aps New interferon beta-like molecules
CA2448233A1 (en) 2001-03-07 2002-09-19 The Procter & Gamble Company Topical composition comprising a three membered cyclic compound-based cosmetic bonding agent
WO2002072059A2 (en) 2001-03-07 2002-09-19 The Procter & Gamble Company Topical composition comprising a functionally alkylating cosmetic bonding agent
JP2004520429A (en) 2001-03-07 2004-07-08 ザ プロクター アンド ギャンブル カンパニー Topical compositions containing functional acylated cosmetic binders
EP1370235A2 (en) 2001-03-07 2003-12-17 The Procter & Gamble Company Topical composition comprising an aldehyde or ketone-based cosmetic bonding agent
CN100489094C (en) 2001-03-23 2009-05-20 金克克国际有限公司 Proteins with altered immunogenicity and methods of making and using the same
CN1536984A (en) 2001-05-30 2004-10-13 Topical composition comprising activated, trans-structured cosmetic bonding agent
MXPA03010860A (en) 2001-05-30 2004-02-17 Procter & Gamble Topical composition comprising a substituted cosmetic bonding agent.
BR0215383A (en) 2001-12-31 2006-11-28 Genencor Int proteases that produce altered immunogenic response and methods of manufacture and use thereof
DK1517710T3 (en) 2002-06-21 2011-07-18 Novo Nordisk Healthcare Ag Pegylated factor VII glycoforms
CN102516386A (en) 2003-10-10 2012-06-27 诺沃挪第克公司 Il-21 derivatives
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
AU2005211362B2 (en) 2004-02-02 2008-03-13 Ambrx, Inc. Modified human interferon polypeptides and their uses
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
JP4990792B2 (en) 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド Compositions of aminoacyl-tRNA synthetases and uses thereof
EP1836316A4 (en) 2004-12-22 2009-07-22 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
NZ555386A (en) 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
ATE529442T1 (en) 2005-06-03 2011-11-15 Ambrx Inc IMPROVED HUMAN INTERFERON MOLECULES AND THEIR USES
JP5335422B2 (en) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Selective reduction and derivatization of engineered proteins containing at least one unnatural cysteine
EP1951890A4 (en) 2005-11-16 2009-06-24 Ambrx Inc Methods and compositions comprising non-natural amino acids
EP2213733A3 (en) 2006-05-24 2010-12-29 Novo Nordisk Health Care AG Factor IX analogues having prolonged in vivo half life
DK2061878T3 (en) 2006-09-08 2014-04-07 Ambrx Inc HYBRID SUPPRESSOR TRNA FOR ANIMAL CELLS
EP2615108B1 (en) 2006-09-08 2016-10-26 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and thier uses
MX2009002526A (en) 2006-09-08 2009-04-16 Ambrx Inc Suppressor trna transcription in vertebrate cells.
WO2008076407A2 (en) 2006-12-15 2008-06-26 Lifebond Ltd. Gelatin-transglutaminase hemostatic dressings and sealants
ATE554785T1 (en) 2007-03-30 2012-05-15 Ambrx Inc MODIFIED FGF-21 POLYPEPTIDES AND THEIR USE
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EP2930182A1 (en) 2007-11-20 2015-10-14 Ambrx, Inc. Modified insulin polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
CN104031393B (en) 2008-06-18 2017-08-01 生命连结有限公司 Improved cross-linked composition
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
CN102232085A (en) 2008-09-26 2011-11-02 Ambrx公司 Modified animal erythropoietin polypeptides and their uses
MX2011003196A (en) 2008-09-26 2011-04-27 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines.
BR112012015597A2 (en) 2009-12-21 2017-01-31 Ambrx Inc modified porcine somatotropin peptides and their uses
MX349301B (en) 2009-12-21 2017-07-21 Ambrx Inc Modified bovine somatotropin polypeptides and their uses.
CA2782863A1 (en) 2009-12-22 2011-06-30 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
US9815876B2 (en) 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
ES2567174T3 (en) 2010-08-05 2016-04-20 Lifebond Ltd Dry composition in dressings and wound adhesives
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
HUE045845T2 (en) 2010-08-17 2021-12-28 Ambrx Inc Modified relaxin polypeptides and their uses
AR083006A1 (en) 2010-09-23 2013-01-23 Lilly Co Eli FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
CA2840552A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AU2013270684B2 (en) 2012-06-08 2018-04-19 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
ES2907763T3 (en) 2012-08-31 2022-04-26 Sutro Biopharma Inc Modified amino acids comprising an azido group
ES2658039T3 (en) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EA036697B1 (en) 2014-10-24 2020-12-09 Бристол-Майерс Сквибб Компани Modified fgf-21 polypeptides and uses thereof
CA3052639A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
FI3849614T3 (en) 2018-09-11 2024-02-08 Ambrx Inc Interleukin-2 polypeptide conjugates and their uses
JP2022512746A (en) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド Interleukin-10 polypeptide complex, its dimer, and their use
BR112021015832A2 (en) 2019-02-12 2022-01-18 Ambrx Inc Compositions containing antibody-tlr agonist conjugates, methods and uses thereof
AU2021233909A1 (en) 2020-03-11 2022-09-29 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
WO2022212899A1 (en) 2021-04-03 2022-10-06 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE3440141A1 (en) * 1984-11-02 1986-05-07 Heiner Dipl.-Chem. Dr. 8000 München Eckert Use of bistrichloromethyl carbonate as a proreagent for phosgene
HUT64022A (en) * 1989-04-19 1993-11-29 Enzon Inc Process for producing active polyalkileneoxide carbonates for the modification of polypeptides
CA2038935C (en) * 1989-08-07 1998-12-08 Luciana Sartore Biologically active drug polymer derivatives and method for preparing same
DD287951A5 (en) * 1989-09-15 1991-03-14 Adw Zi F. Molekularbiologie,De PROCESS FOR IMMOBILIZING BIOLOGICALLY ACTIVE COMPOUNDS ON POLYOXYALKYLENE GLYCOL AND ITS MONOALKOXY DERIVATIVES
FR2687681B1 (en) * 1992-02-20 1995-10-13 Transgene Sa POLYETHYLENEGLYCOL-HIRUDINE CONJUGATES, THEIR PREPARATION PROCESS AND THEIR USE FOR THE TREATMENT OF THROMBOSES.
AU5006993A (en) * 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
ATE151090T1 (en) * 1993-06-29 1997-04-15 Heylecina Societe Anonyme PRODUCTION OF ACTIVATED CARBAMATES OF POLYALKYLENE GLYCOL AND THEIR USE
US5650234A (en) * 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces

Also Published As

Publication number Publication date
WO1996040791A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
AU5893696A (en) Modification of polypeptides
AU7203496A (en) Novel peptides
AU5235796A (en) o-hydroxyphenyl-s-triazines
AU4780896A (en) Core-board
AU5893796A (en) Modification of polypeptides
AU1030997A (en) Taphane
AU4996696A (en) 2-benzyl-3-arylbenzothiophenes
AU5147496A (en) Fucopeptides
AU4427296A (en) Novel peptide
AU4394396A (en) Modified peptides
AU4224096A (en) Use of phenylcyclohexylcarboxamides
AU5593896A (en) Benzisothiazolyl-substituted aminomethylchromans
AU4382896A (en) Acetylimidazobenzodiazepines
AU5500196A (en) Anti-transpirants
AU7520396A (en) Abl-interactor protein
AU4877196A (en) Derivatives of 3-pyrrolidylidene-2-one-cephalosporines
AU5108596A (en) Morphine-3-esters
AU5284296A (en) Immune-evading proteins
AU6890696A (en) Peptide derivatives
AU5013796A (en) Wireclamp
AU6890596A (en) Peptide derivatives
AU5107096A (en) Haemodialyser
AU6153396A (en) E6ap-binding proteins
AU5161296A (en) Anti-haemorrhagic peptides
AU4569496A (en) Tetralinyl- and indanyl-ethylamides